Apr 30 |
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
|
Apr 25 |
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
|
Apr 20 |
XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years
|
Mar 19 |
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
|
Mar 8 |
XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023
|
Mar 8 |
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
|
Feb 28 |
XOMA to Present at Upcoming Investor Conferences in March
|
Feb 16 |
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
|
Jan 18 |
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
|
Jan 8 |
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
|